Alejandro Macchia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4992809/publications.pdf

Version: 2024-02-01

53 papers	2,687 citations	218677 26 h-index	182427 51 g-index
62 all docs	62 docs citations	62 times ranked	3784 citing authors

#	Article	IF	Citations
1	CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities. American Journal of Medicine, 2008, 121, 58-65.	1.5	275
2	Fish Oil and Postoperative Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2012, 308, 2001.	7.4	201
3	A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal, 2007, 153, 1037-1047.	2.7	200
4	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 277-283.	2.8	147
5	Long-Term Results After a Telephone Intervention in Chronic Heart Failure. Journal of the American College of Cardiology, 2010, 56, 372-378.	2.8	126
6	Unrecognised ventricular dysfunction in COPD. European Respiratory Journal, 2012, 39, 51-58.	6.7	119
7	Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 463-468.	2.8	119
8	Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal, 2010, 159, 245-257.	2.7	106
9	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. European Journal of Heart Failure, 2005, 7, 904-909.	7.1	101
10	Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. Journal of Cardiovascular Medicine, 2006, 7, 347-350.	1.5	96
11	The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. European Journal of Heart Failure, 2007, 9, 942-948.	7.1	90
12	Nâ€3 Polyunsaturated Fatty Acids to Prevent Atrial Fibrillation: Updated Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2013, 2, e005033.	3.7	89
13	Previous prescription of Î²-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis*. Critical Care Medicine, 2012, 40, 2768-2772.	0.9	86
14	Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. Journal of Hypertension, 2010, 28, 24-34.	0.5	80
15	Total myocardial revascularization with arterial conduits: Radial artery combined with internal thoracic arteries. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 911-916.	0.8	72
16	Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure, 2011, 17, 850-859.	1.7	64
17	High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study. Diabetic Medicine, 2009, 26, 864-871.	2.3	62
18	Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. European Heart Journal, 2006, 27, 2217-2223.	2.2	60

#	Article	IF	Citations
19	Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. European Journal of Clinical Pharmacology, 2008, 64, 627-634.	1.9	49
20	Depression worsens outcomes in elderly patients with heart failure: An analysis of 48,117 patients in a community setting. European Journal of Heart Failure, 2008, 10, 714-721.	7.1	46
21	Educational inequalities in obesity, abdominal obesity, and metabolic syndrome in seven Latin American cities: the CARMELA Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 550-556.	2.8	45
22	Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in nonâ€“Q-wave acute myocardial infarction. American Journal of Cardiology, 1999, 83, 515-518.	1.6	41
23	Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country. JAMA Network Open, 2021, 4, e2130800.	5.9	40
24	Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. Journal of Membrane Biology, 2005, 206, 117-128.	2.1	34
25	The Ï‰-3 fatty acids for Prevention of Post-Operative Atrial Fibrillation trialâ€”rationale and design. American Heart Journal, 2011, 162, 56-63.e3.	2.7	31
26	The rationale and design of the FORÏ‰ARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal, 2009, 157, 423-427.	2.7	29
27	Myocardial revascularization with radial and mammary arteries: initial and mid-term results. Annals of Thoracic Surgery, 2000, 70, 1378-1383.	1.3	27
28	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)â€“Prevenzione scoring. American Heart Journal, 2006, 151, 754.e7-754.e17.	2.7	26
29	Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk. European Journal of Clinical Pharmacology, 2009, 65, 1131-1138.	1.9	25
30	Statins but Not Aspirin Reduce Thrombotic Risk Assessed by Thrombin Generation in Diabetic Patients without Cardiovascular Events: The RATIONAL Trial. PLoS ONE, 2012, 7, e32894.	2.5	25
31	Plasma Phospholipid Omegaâ€3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial. Journal of the American Heart Association, 2013, 2, e000397.	3.7	24
32	Circulating cardiac biomarkers and postoperative atrial fibrillation in the <scp>OPERA</scp> trial. European Journal of Clinical Investigation, 2015, 45, 170-178.	3.4	23
33	Exploratory Analysis on the Use of Statins with or without n-3 PUFA and Major Events in Patients Discharged for Acute Myocardial Infarction: An Observational Retrospective Study. PLoS ONE, 2013, 8, e62772.	2.5	18
34	Multivessel versus Single Vessel Angioplasty in Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Metaanalysis. PLoS ONE, 2016, 11, e0148756.	2.5	18
35	Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. European Heart Journal, 2012, 33, 515-522.	2.2	16
36	COVID-19 among the inhabitants of the slums in the city of Buenos Aires: a population-based study. BMJ Open, 2021, 11, e044592.	1.9	12

#	Article	IF	Citations
37	Macitentan and Pulmonary Arterial Hypertension. New England Journal of Medicine, 2014, 370, 81-83.	27.0	11
38	Clinical Trials Using Vasodilators in Pulmonary Arterial Hypertension:Where Do We Go from Here?. Reviews on Recent Clinical Trials, 2011, 6, 228-234.	0.8	6
39	Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials. The Lancet Regional Health Americas, 2022, 9, 100196.	2.6	5
40	Cardiovascular and other risk factors among people who live in slums in Buenos Aires, Argentina. Public Health, 2019, 170, 38-44.	2.9	3
41	Use of alternative care sites during the COVID-19 pandemic in the city of Buenos Aires, Argentina. Public Health, 2021, 194, 14-16.	2.9	3
42	Evaluation of the first level of care for tuberculosis control in Buenos Aires, Argentina. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2021, 45, 1.	1.1	2
43	An analysis of death trends in Argentina, 1990-2017, with emphasis on the effects of economic crises. Journal of Global Health, 2020, 10, .	2.7	2
44	Anemia and chronic heart failure: from pathophysiologic mechanisms to clinical trial designs. Expert Review of Cardiovascular Therapy, 2009, 7, 139-145.	1.5	1
45	Reply. Journal of the American College of Cardiology, 2013, 61, 1552-1553.	2.8	1
46	On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate. European Journal of Clinical Pharmacology, 2015, 71, 449-459.	1.9	1
47	Health as a Human Right: A Fake News in a Post-human World?. Development, 2020, 63, 270-276.	1.0	1
48	Anti-human skeletal muscle glycolipid antibodies in unstable angina. American Heart Journal, 2001, 141, 780-783.	2.7	0
49	Assessment of survival benefit after lung transplantation by patient diagnosis. Journal of Heart and Lung Transplantation, 2003, 22, 705.	0.6	0
50	Determinants of Late-Onset Heart Failure in Myocardial Infarction Survivors: GISSI Prevenzione Trial Results. Revista Espanola De Cardiologia (English Ed), 2005, 58, 1266-1272.	0.6	0
51	DIAL Trial Not Included in a Review of Health Failure Management Programs. Journal of the American College of Cardiology, 2010, 56, 159-160.	2.8	0
52	Reply. Journal of the American College of Cardiology, 2013, 62, 84-85.	2.8	0
53	The challenges of estimations: a Southern world view. European Heart Journal Supplements, 2018, 20, C23-C24.	0.1	0